All In Biotech

Drug Trial Radar · NCT00113269

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Aug 11, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

May 2005

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.

Conditions

  • Kidney Transplantation

Interventions

  • basiliximabDrug

    IV

  • rabbit anti-thymocyte globulinDrug

    IV

  • tacrolimusDrug

    oral

  • alemtuzumabDrug

    Intravenous (IV)

  • mycophenolate mofetilDrug

    oral

  • steroidsDrug

    IV and/or oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 MonthsTime frame: 6 months

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Livingston, New Jersey

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Hawthorne, New York

  • Site not named

    New York, New York

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Danville, Pennsylvania

  • Site not named

    Harrisburg, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    San Antonio, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Madison, Wisconsin

  • Site not named

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.